Alzheimer’s disease according to some there was even among our ancestors. While the disease was described in the beginning of last century and about the same time began the search for medication. Of course, in this area there is significant progress, but to protect or cure our body from this neurodegenerative process is, unfortunately, not until now. However, scientists are still trying to do it and recently a group of researchers from the University of Queensland the start of testing is quite promising method.
According to statistics, Parkinson’s disease is the second most common neurodegenerative disease in the world. From it annually affects about 10 million people. The basic mechanism of the disease — chronic inflammation of the neurons in the brain, accompanied by protein deposition, loss of control over physical activity and other lesions of the Central nervous system. It is on the process of inflammation and decided to draw the attention of the associate Professor of the medical faculty of Trent Woodruff Professor Matt Cooper.
“Our team discovered that a small molecule MCC950 stopped the development of Parkinson’s disease in several animal models. We used this discovery to develop improved drugs of new type and plan to start clinical trials by 2020.”
The essence of drug action: the researchers found that many patients suffering from Alzheimer’s, the main development factor is the protein complex NLRP3. It not only causes protein adhesion to inflamed brain cells, but also circulating in the blood. Synthetic molecule MCC950 perceives this protein as a target and locks it.
“Inflammation is associated with increased local temperature and we can say that the molecule MCC950 as if “cools the brain” that stops the inflammation and allows the neurons to function normally again. During the first experiments on laboratory animals we were able to achieve significant recovery of motor activity.”
This and other news you can discuss in our chat in Telegram.